임상시험 지원 서비스 시장 규모, 점유율, 동향 분석 보고서 : 단계별, 서비스별, 스폰서별, 지역별, 부문별 예측(2026-2033년)

Clinical Trials Support Services Market Summary

The global clinical trials support services market size was estimated at USD 25.62 billion in 2025 and is projected to reach USD 47.00 billion by 2033, growing at a CAGR of 7.93% from 2026 to 2033. The global market is projected to expand rapidly due to rising demand for trials in emerging economies, increasing R&D investment, and a growing number of contract research organizations (CROs).

The pharmaceutical firms' (R&D) venture has been steadily growing every year, mainly due to patent expirations. An ordinary patent terminates after 20 years; in the pharmaceutical area, there is an arrangement that provides for the entry of a generic version of the medication into the market following a period of 10 years. Thus, companies are increasing their R&D investments to accelerate the development of drugs, thereby expanding the entire market.

Clinical trials support services are quite useful in the event of a drug, such as assay design and clinical testing. It also covers tasks such as strengthening clinical test locations, securing and storing research medications, calculating drug dosages, and handling kits. Preclinical groundwork and research are supported by clinical test services, which include clinical test site assistance, obtaining & storing study drugs, blinding of drugs for studies, patient recruitment, coordination, and reconciliation of returned medications.

In addition, growing adoption of new technologies has fueled market growth. Many software tools for data management are referred to as "Clinical Data Management" (CDM) systems. Multicentric trials require CDM systems to handle massive volumes of data. The majority of CDM systems used by pharmaceutical companies are commercial, but a few open-source tools are also available. Oracle Clinical, Clintrial, Oracle Clinical, Macro, RAVE, and eClinical Suite are common CDM tools. Maintaining an audit record of data management actions is important in regulatory submissions. These CDM tools help ensure the audit trail and manage discrepancies. The CDM activities include data collection, CRF annotation, CRF tracking, database design, data entry, medical coding, data validation, discrepancy management, and database lock.

Global Clinical Trials Support Services Market Report Segmentation

This report forecasts revenue growth at the regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the clinical trials support services market report based on the phases, service,sponsor and region:

• Phases Outlook (Revenue, USD Million, 2021 - 2033)
• Phase I
• Phase II
• Phase III
• Phase IV
• Service Outlook (Revenue, USD Million, 2021 - 2033)
• Clinical Trial Site Management
• Patient Recruitment Management
  • Patient recruitment & Registry Services
  • Patient retention
  • Others
• Data Management
• Administrative Staff
• IRB
• Others
• Sponsor Outlook (Revenue, USD Million, 2021 - 2033)
• Pharmaceutical & biopharmaceutical companies
• Medical device companies
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Thailand
  • South Korea
  • Australia
• Latin America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Oman
  • Qatar
  • Kuwait

Table of Contents

Chapter 1. Research Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Phases
  • 1.2.2. Service
  • 1.2.3. Sponsor
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
  • 1.7.2. Top-Down Analysis
  • 1.7.3. Botton-Up Approach
  • 1.7.4. Multivariate Analysis
• 1.8. List of Secondary Sources
• 1.9. List of Abbreviations
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Clinical Trials Support Services Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
  • 3.2.3. Market Opportunity Analysis
• 3.3. R&D Spending Analysis
• 3.4. Technology Landscape
• 3.5. Clinical Trial Volume Analysis, 2024
• 3.6. Pricing Analysis
• 3.7. Tariff and Trade Agreement Impact Analysis
• 3.8. Value Chain Analysis
  • 3.8.1. Supply Trends
  • 3.8.2. Demand Trends
• 3.9. Market Analysis Tools
  • 3.9.1. Porter's Five Force Analysis
  • 3.9.2. PESTEL by SWOT Analysis

Chapter 4. Clinical Trials Support Services Market: Phases Estimates & Trend Analysis

• 4.1. Clinical Trials Support Services Market, by Phases: Segment Dashboard
• 4.2. Clinical Trials Support Services Market, by Phases: Movement Analysis
• 4.3. Clinical Trials Support Services Market Estimates & Forecasts, by Phases, 2021 - 2033 (USD Million)
• 4.4. Phase I
  • 4.4.1. Phase I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Phase II
  • 4.5.1. Phase II Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Phase III
  • 4.6.1. Phase III Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.7. Phase IV
  • 4.7.1. Phase IV Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Clinical Trials Support Services Market: Service Estimates & Trend Analysis

• 5.1. Clinical Trials Support Services Market, by Service: Segment Dashboard
• 5.2. Clinical Trials Support Services Market, by Service: Movement Analysis
• 5.3. Clinical Trials Support Services Market Estimates & Forecasts, by Service, 2021 - 2033 (USD Million)
• 5.4. Clinical Trial Site Management
  • 5.4.1. Clinical Trial Site Management Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Patient Recruitment Management
  • 5.5.1. Patient Recruitment Management Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.2. Patient Recruitment & Registry Services
    • 5.5.2.1. Patient Recruitment & Registry Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.3. Patient Retention
    • 5.5.3.1. Patient Retention Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.4. Others
    • 5.5.4.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Data Management
  • 5.6.1. Data Management Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.7. Administrative Staff
  • 5.7.1. Administrative Staff Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.8. IRB
  • 5.8.1. IRB Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.9. Others
  • 5.9.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Clinical Trials Support Services Market: Sponsor Estimates & Trend Analysis

• 6.1. Clinical Trials Support Services Market, by Sponsor: Segment Dashboard
• 6.2. Clinical Trials Support Services Market, by Sponsor: Movement Analysis
• 6.3. Clinical Trials Support Services Market Estimates & Forecasts, by Sponsor, 2021 - 2033 (USD Million)
• 6.4. Pharmaceutical & Biopharmaceutical Companies
  • 6.4.1. Pharmaceutical & Biopharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Medical Device Companies
  • 6.5.1. Medical Device Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Others
  • 6.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Clinical Trials Support Services Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Dashboard
• 7.2. Regional Market Share Analysis, 2025 & 2033
• 7.3. North America
  • 7.3.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.2. U.S
    • 7.3.2.1. Key Country Dynamics
    • 7.3.2.2. Competitive Scenario
    • 7.3.2.3. Regulatory Framework
    • 7.3.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.3. Canada
    • 7.3.3.1. Key Country Dynamics
    • 7.3.3.2. Competitive Scenario
    • 7.3.3.3. Regulatory Framework
    • 7.3.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.4. Mexico
    • 7.3.4.1. Key Country Dynamics
    • 7.3.4.2. Competitive Scenario
    • 7.3.4.3. Regulatory Framework
    • 7.3.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.4. Europe
  • 7.4.1. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.2. UK
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Competitive Scenario
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.3. Germany
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Competitive Scenario
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.4. France
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Competitive Scenario
    • 7.4.4.3. Regulatory Framework
    • 7.4.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.5. Italy
    • 7.4.5.1. Key Country Dynamics
    • 7.4.5.2. Competitive Scenario
    • 7.4.5.3. Regulatory Framework
    • 7.4.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.6. Spain
    • 7.4.6.1. Key Country Dynamics
    • 7.4.6.2. Competitive Scenario
    • 7.4.6.3. Regulatory Framework
    • 7.4.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.7. Sweden
    • 7.4.7.1. Key Country Dynamics
    • 7.4.7.2. Competitive Scenario
    • 7.4.7.3. Regulatory Framework
    • 7.4.7.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.8. Denmark
    • 7.4.8.1. Key Country Dynamics
    • 7.4.8.2. Competitive Scenario
    • 7.4.8.3. Regulatory Framework
    • 7.4.8.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.9. Norway
    • 7.4.9.1. Key Country Dynamics
    • 7.4.9.2. Competitive Scenario
    • 7.4.9.3. Regulatory Framework
    • 7.4.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.2. Japan
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.3. China
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Competitive Scenario
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.4. India
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Competitive Scenario
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.5. Thailand
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Competitive Scenario
    • 7.5.5.3. Regulatory Framework
    • 7.5.5.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.6. South Korea
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Competitive Scenario
    • 7.5.6.3. Regulatory Framework
    • 7.5.6.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.7. Australia
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Competitive Scenario
    • 7.5.7.3. Regulatory Framework
    • 7.5.7.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Latin America
  • 7.6.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.2. Brazil
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.3. Argentina
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.4. Colombia
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Competitive Scenario
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. Colombia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.7. MEA
  • 7.7.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.2. South Africa
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Competitive Scenario
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.3. Saudi Arabia
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Competitive Scenario
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.4. UAE
    • 7.7.4.1. Key Country Dynamics
    • 7.7.4.2. Competitive Scenario
    • 7.7.4.3. Regulatory Framework
    • 7.7.4.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.5. Kuwait
    • 7.7.5.1. Key Country Dynamics
    • 7.7.5.2. Competitive Scenario
    • 7.7.5.3. Regulatory Framework
    • 7.7.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.6. Qatar
    • 7.7.6.1. Key Country Dynamics
    • 7.7.6.2. Competitive Scenario
    • 7.7.6.3. Regulatory Framework
    • 7.7.6.4. Qatar Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.7. Oman
    • 7.7.7.1. Key Country Dynamics
    • 7.7.7.2. Competitive Scenario
    • 7.7.7.3. Regulatory Framework
    • 7.7.7.4. Oman Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Key Participant Categorization
  • 8.1.1. Market Leaders
  • 8.1.2. Emerging Players
• 8.2. Market Assessment Analysis, 2025 (Heat Map Analysis)
• 8.3. Company Profiles
  • 8.3.1. Charles River Laboratories International, Inc.
    • 8.3.1.1. Company Overview
    • 8.3.1.2. Financial Performance
    • 8.3.1.3. Service Benchmarking
    • 8.3.1.4. Strategic Initiatives
  • 8.3.2. Wuxi Apptec, Inc
    • 8.3.2.1. Company Overview
    • 8.3.2.2. Financial Performance
    • 8.3.2.3. Service Benchmarking
    • 8.3.2.4. Strategic Initiatives
  • 8.3.3. Iqvia Holdings, Inc
    • 8.3.3.1. Company Overview
    • 8.3.3.2. Financial Performance
    • 8.3.3.3. Service Benchmarking
    • 8.3.3.4. Strategic Initiatives
  • 8.3.4. Syneos Health, Inc.
    • 8.3.4.1. Company Overview
    • 8.3.4.2. Financial Performance
    • 8.3.4.3. Service Benchmarking
    • 8.3.4.4. Strategic Initiatives
  • 8.3.5. Eurofins Scientific
    • 8.3.5.1. Company Overview
    • 8.3.5.2. Financial Performance
    • 8.3.5.3. Service Benchmarking
    • 8.3.5.4. Strategic Initiatives
  • 8.3.6. PPD, Inc. (Pharmaceutical Product Development)
    • 8.3.6.1. Company Overview
    • 8.3.6.2. Financial Performance
    • 8.3.6.3. Service Benchmarking
    • 8.3.6.4. Strategic Initiatives
  • 8.3.7. Icon Plc
    • 8.3.7.1. Company Overview
    • 8.3.7.2. Financial Performance
    • 8.3.7.3. Service Benchmarking
    • 8.3.7.4. Strategic Initiatives
  • 8.3.8. Laboratory Corporation of America Holdings (Labcorp)
    • 8.3.8.1. Company Overview
    • 8.3.8.2. Financial Performance
    • 8.3.8.3. Service Benchmarking
    • 8.3.8.4. Strategic Initiatives
  • 8.3.9. Alcura
    • 8.3.9.1. Company Overview
    • 8.3.9.2. Financial Performance
    • 8.3.9.3. Service Benchmarking
    • 8.3.9.4. Strategic Initiatives
  • 8.3.10. Parexel International Corporation
    • 8.3.10.1. Company Overview
    • 8.3.10.2. Financial Performance
    • 8.3.10.3. Service Benchmarking
    • 8.3.10.4. Strategic Initiative